Literature DB >> 19129457

Determinants flanking the CD4 binding loop modulate macrophage tropism of human immunodeficiency virus type 1 R5 envelopes.

Maria José Duenas-Decamp1, Paul J Peters, Dennis Burton, Paul R Clapham.   

Abstract

Human immunodeficiency virus type 1 R5 viruses vary extensively in phenotype. Thus, R5 envelopes (env) in the brain tissue of individuals with neurological complications are frequently highly macrophage-tropic. Macrophage tropism correlates with the capacity of the envelope to exploit low CD4 levels for infection. In addition, the presence of an asparagine at residue 283 within the CD4 binding site has been associated with brain-derived envelopes, increased env-CD4 affinity, and enhanced macrophage tropism. Here, we identify additional envelope determinants of R5 macrophage tropism. We compared highly macrophage-tropic (B33) and non-macrophage-tropic (LN40) envelopes from brain and lymph node specimens of one individual. We first examined the role of residue 283 in macrophage tropism. Introduction of N283 into LN40 (T283N) conferred efficient macrophage infectivity. In contrast, substitution of N283 for the more conserved threonine in B33 had little effect on macrophage infection. Thus, B33 carried determinants for macrophage tropism that were independent of N283. We prepared chimeric B33/LN40 envelopes and used site-directed mutagenesis to identify additional determinants. The determinants of macrophage tropism that were identified included residues on the CD4 binding loop flanks that were proximal to CD4 contact residues and residues in the V3 loop. The same residues affected sensitivity to CD4-immunoglobulin G inhibition, consistent with an altered env-CD4 affinity. We predict that these determinants alter exposure of CD4 contact residues. Moreover, the CD4 binding loop flanks are variable and may contribute to a general mechanism for protecting proximal CD4 contact residues from neutralizing antibodies. Our results have relevance for env-based vaccines that will need to expose critical CD4 contact residues to the immune system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19129457      PMCID: PMC2648272          DOI: 10.1128/JVI.02133-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding.

Authors:  U O'Doherty; W J Swiggard; M H Malim
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system.

Authors:  R B DuBridge; P Tang; H C Hsia; P M Leong; J H Miller; M P Calos
Journal:  Mol Cell Biol       Date:  1987-01       Impact factor: 4.272

3.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

4.  Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate.

Authors:  Paul R Gorry; Joann Taylor; Geoffrey H Holm; Andrew Mehle; Tom Morgan; Mark Cayabyab; Michael Farzan; Hui Wang; Jeanne E Bell; Kevin Kunstman; John P Moore; Steven M Wolinsky; Dana Gabuzda
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Enhanced HIV replication in macrophage colony-stimulating factor-treated monocytes.

Authors:  D C Kalter; M Nakamura; J A Turpin; L M Baca; D L Hoover; C Dieffenbach; P Ralph; H E Gendelman; M S Meltzer
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

6.  Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers.

Authors:  P Simmonds; P Balfe; J F Peutherer; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

7.  Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages.

Authors:  Paul J Peters; Jayanta Bhattacharya; Samantha Hibbitts; Matthias T Dittmar; Graham Simmons; Jeanne Bell; Peter Simmonds; Paul R Clapham
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization.

Authors:  Emma T Crooks; Pengfei Jiang; Michael Franti; Sharon Wong; Michael B Zwick; James A Hoxie; James E Robinson; Penny L Moore; James M Binley
Journal:  Virology       Date:  2008-06-09       Impact factor: 3.616

9.  Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract.

Authors:  Saurabh Mehandru; Michael A Poles; Klara Tenner-Racz; Amir Horowitz; Arlene Hurley; Christine Hogan; Daniel Boden; Paul Racz; Martin Markowitz
Journal:  J Exp Med       Date:  2004-09-13       Impact factor: 14.307

10.  CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.

Authors:  Jason M Brenchley; Timothy W Schacker; Laura E Ruff; David A Price; Jodie H Taylor; Gregory J Beilman; Phuong L Nguyen; Alexander Khoruts; Matthew Larson; Ashley T Haase; Daniel C Douek
Journal:  J Exp Med       Date:  2004-09-13       Impact factor: 14.307

View more
  50 in total

1.  A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection.

Authors:  Thomas Musich; Paul J Peters; Maria José Duenas-Decamp; Maria Paz Gonzalez-Perez; James Robinson; Susan Zolla-Pazner; Jonathan K Ball; Katherine Luzuriaga; Paul R Clapham
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

Review 2.  Coreceptors and HIV-1 pathogenesis.

Authors:  Paul R Gorry; Petronela Ancuta
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

3.  Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Authors:  Kieran Cashin; Michael Roche; Jasminka Sterjovski; Anne Ellett; Lachlan R Gray; Anthony L Cunningham; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

4.  Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities.

Authors:  Sarah B Joseph; Kathryn T Arrildt; Adrienne E Swanstrom; Gretja Schnell; Benhur Lee; James A Hoxie; Ronald Swanstrom
Journal:  J Virol       Date:  2013-12-04       Impact factor: 5.103

5.  Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.

Authors:  Sarah B Joseph; Laura P Kincer; Natalie M Bowman; Chris Evans; Michael J Vinikoor; Christopher K Lippincott; Magnus Gisslén; Serena Spudich; Prema Menezes; Kevin Robertson; Nancie Archin; Angela Kashuba; Joseph J Eron; Richard W Price; Ronald Swanstrom
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

6.  Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors.

Authors:  Richard J P Brown; Paul J Peters; Catherine Caron; Maria Paz Gonzalez-Perez; Leanne Stones; Chiambah Ankghuambom; Kemebradikumo Pondei; C Patrick McClure; George Alemnji; Stephen Taylor; Paul M Sharp; Paul R Clapham; Jonathan K Ball
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

7.  Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism.

Authors:  Olivia O'Connell; Alexander Repik; Jacqueline D Reeves; Maria Paz Gonzalez-Perez; Briana Quitadamo; Elizabeth D Anton; Maria Duenas-Decamp; Paul Peters; Rongheng Lin; Susan Zolla-Pazner; Davide Corti; Aaron Wallace; Shixia Wang; Xiang-Peng Kong; Shan Lu; Paul R Clapham
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

8.  Modulation of HIV-1 macrophage-tropism among R5 envelopes occurs before detection of neutralizing antibodies.

Authors:  Kathryn H Richards; Marlén Mi Aasa-Chapman; Aine McKnight; Paul R Clapham
Journal:  Retrovirology       Date:  2010-05-27       Impact factor: 4.602

9.  Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5.

Authors:  Hamid Salimi; Michael Roche; Nicholas Webb; Lachlan R Gray; Kelechi Chikere; Jasminka Sterjovski; Anne Ellett; Steve L Wesselingh; Paul A Ramsland; Benhur Lee; Melissa J Churchill; Paul R Gorry
Journal:  J Leukoc Biol       Date:  2012-10-17       Impact factor: 4.962

10.  Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.

Authors:  Jesus F Salazar-Gonzalez; Maria G Salazar; Brandon F Keele; Gerald H Learn; Elena E Giorgi; Hui Li; Julie M Decker; Shuyi Wang; Joshua Baalwa; Matthias H Kraus; Nicholas F Parrish; Katharina S Shaw; M Brad Guffey; Katharine J Bar; Katie L Davis; Christina Ochsenbauer-Jambor; John C Kappes; Michael S Saag; Myron S Cohen; Joseph Mulenga; Cynthia A Derdeyn; Susan Allen; Eric Hunter; Martin Markowitz; Peter Hraber; Alan S Perelson; Tanmoy Bhattacharya; Barton F Haynes; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.